Market Overview

UPDATE: Piper Jaffray Downgrades XenoPort to Neutral on Drug Commercialization Delays

Related XNPT
Catalysts To Watch For In RBC Capital's 2015 Top Small-Cap Biotechs
Jefferies Weighs In On Specialty Pharmaceuticals After Management Meetings, Raises Price Targets On 5 Stocks

Piper Jaffray reduced its rating on XenoPort (NASDAQ: XNPT) from Overweight to Neutral with a reiterated $12 price target.

Piper Jaffray said, "Given the long road ahead for '829, our cautious view on the prospects for a partnership for '829 or outright sale of the company in the near-term and the lack of visibility on cash generation (i.e., continued lackluster prescription trends for Horizant and niche-like potential for arbaclofen placarbil for spasticity), we believe upside for XNPT shares is limited in the context of an enterprise value of $430M."

XenoPort closed at $11.91 on Thursday.

Latest Ratings for XNPT

Jan 2015JefferiesMaintainsBuy
Apr 2014JefferiesInitiates Coverage onBuy
Jun 2013Morgan StanleyDowngradesEqual-weightUnderweight

View More Analyst Ratings for XNPT
View the Latest Analyst Ratings

Posted-In: Piper JaffrayAnalyst Color Downgrades Intraday Update Analyst Ratings


Related Articles (XNPT)

Around the Web, We're Loving...